Brian talks to finance news, page-11

Come-on.....you also want cheapies (i.e. 2c), ask yourself honestly.
It will all depend on the next result in 3 months time......and to new investors, DYOR.
If you believe that the bad result were due to data collection, buy, if not, don't buy.
BTW, the clinical trials in the US will start in December so they have 2 month to sort it out, but what is interest to me is RAP has re-iterated the poor protocol with the recent clinical trials and none of the hospitals has debunked this.....that says something doesn't it????